A new study has recently been reported: TAVI Fails Noninferiority to Surgery in Younger Patients
6/24/2024 PARIS — Despite some potential advantages, transcatheter aortic valve implantation (TAVI) failed to meet the primary prespecified threshold for noninferiority to surgical aortic valve replacement in younger low-risk patients with severe disease in a multicenter randomized trial.
Although the two approaches performed similarly in the tricuspid cohort at 1 year, there were fewer primary adverse outcomes in the bicuspid cohort after surgical aortic valve replacement than after TAVI, preventing noninferiority overall, reported Ole De Backer, MD, PhD, an interventional cardiologist at the Heart Center, Rigshospitalet, Copenhagen, Denmark.
"There are many studies comparing TAVI to surgical aortic valve replacement, but these have largely enrolled older patients — typically 75 years or at least 70 years or older — and they have generally excluded those with bicuspid valve stenosis," De Backer said.
This new trial, called NOTION-2, "is the first-ever randomized trial in younger low-risk patients," explained De Backer, who presented the findings during the major late-breaker session here at the Congress of the European Association of Percutaneous Coronary Interventions (EuroPCR) 2024.
6/24/2024 PARIS — Despite some potential advantages, transcatheter aortic valve implantation (TAVI) failed to meet the primary prespecified threshold for noninferiority to surgical aortic valve replacement in younger low-risk patients with severe disease in a multicenter randomized trial.
Although the two approaches performed similarly in the tricuspid cohort at 1 year, there were fewer primary adverse outcomes in the bicuspid cohort after surgical aortic valve replacement than after TAVI, preventing noninferiority overall, reported Ole De Backer, MD, PhD, an interventional cardiologist at the Heart Center, Rigshospitalet, Copenhagen, Denmark.
"There are many studies comparing TAVI to surgical aortic valve replacement, but these have largely enrolled older patients — typically 75 years or at least 70 years or older — and they have generally excluded those with bicuspid valve stenosis," De Backer said.
This new trial, called NOTION-2, "is the first-ever randomized trial in younger low-risk patients," explained De Backer, who presented the findings during the major late-breaker session here at the Congress of the European Association of Percutaneous Coronary Interventions (EuroPCR) 2024.
